Your session is about to expire
← Back to Search
Enzyme
Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration (AMD Trial)
Phase 2
Waitlist Available
Led By Steven D Schwartz, M.D.
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Summary
The purpose of this study is to determine whether microplasmin given by intravitreal injection is effective and safe for the treatment of wet age-related macular degeneration (AMD) in patients who have focal vitreomacular adhesion (VMA)
Eligible Conditions
- Age-Related Macular Degeneration
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: microplasmin, intravitreal injectionExperimental Treatment1 Intervention
Subjects will receive one intravitreal injection of microplasmin on Day 0.
Group II: PlaceboPlacebo Group1 Intervention
Subjects will receive one intravitreal injection of the placebo on Day 0.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ocriplasmin
FDA approved
Find a Location
Who is running the clinical trial?
ThromboGenicsIndustry Sponsor
30 Previous Clinical Trials
4,858 Total Patients Enrolled
University of California, Los AngelesLead Sponsor
1,567 Previous Clinical Trials
10,266,970 Total Patients Enrolled
Steven D Schwartz, M.D.Principal InvestigatorUniversity of California, Los Angeles